LENSAR, Inc. (NASDAQ:LNSR) Short Interest Update

LENSAR, Inc. (NASDAQ:LNSR) saw a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 505,438 shares, a drop of 45.7% from the June 15th total of 931,678 shares. Based on an average daily trading volume, of 185,422 shares, the short-interest ratio is presently 2.7 days. Approximately 12.0% of the shares of the company are sold short.

LENSAR Stock Performance

Shares of LNSR stock remained flat at $5.67 on Thursday. The stock had a trading volume of 18,770 shares, compared to its average volume of 88,207. The firm has a market cap of $69.64 million, a PE ratio of -9.78 and a beta of 0.87. LENSAR has a 52-week low of $5.06 and a 52-week high of $13.43. The stock’s 50-day simple moving average is $5.85 and its 200 day simple moving average is $8.26.

LENSAR (NASDAQ:LNSR) last issued its quarterly earnings data on Friday, May 8th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $0.18 by $1.38. The company had revenue of $13.43 million during the quarter, compared to analyst estimates of $13.40 million. LENSAR had a negative return on equity of 183.19% and a net margin of 50.94%.

Analyst Ratings Changes

Several equities analysts have issued reports on LNSR shares. Wall Street Zen cut shares of LENSAR from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of LENSAR from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Finally, Lake Street Capital raised shares of LENSAR from a “hold” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Wednesday, April 1st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Investors Weigh In On LENSAR

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Credit Industriel ET Commercial boosted its holdings in shares of LENSAR by 0.8% in the fourth quarter. Credit Industriel ET Commercial now owns 124,483 shares of the company’s stock worth $1,448,000 after buying an additional 1,000 shares during the last quarter. BNP Paribas Financial Markets grew its position in LENSAR by 129.0% during the third quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company’s stock valued at $25,000 after buying an additional 1,131 shares during the period. JPMorgan Chase & Co. increased its holdings in LENSAR by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 5,928 shares of the company’s stock valued at $73,000 after buying an additional 1,254 shares during the last quarter. Barclays PLC increased its holdings in LENSAR by 10.3% during the fourth quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after buying an additional 1,389 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in LENSAR by 0.3% during the third quarter. Vanguard Group Inc. now owns 507,603 shares of the company’s stock valued at $6,269,000 after buying an additional 1,446 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.